Literature DB >> 10756076

Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain.

M Bernaudin1, A Bellail, H H Marti, A Yvon, D Vivien, I Duchatelle, E T Mackenzie, E Petit.   

Abstract

Erythropoietin (Epo), the major hormone controlling the hypoxia-induced increase in the number of erythrocytes, has also a functional role in the brain. However, few data exist as to the cellular source of brain-derived Epo as well as to the molecular mechanisms that control Epo expression in the central nervous system. Using patch-clamp and RT-PCR methods, we provide direct evidence that, besides astrocytes, neurons are a source of Epo in the brain. Both the astrocytic and neuronal expression of Epo mRNA are induced not only by hypoxia, but also by desferrioxamine (DFX) and cobalt chloride (CoCl(2)), two agents known to mimic the hypoxic induction of Epo in hepatoma cells. This induction is blocked by cycloheximide suggesting that de novo protein synthesis is required. Furthermore, the addition of H(2)O(2) decreases the hypoxia-induced Epo mRNA levels. These data indicate that, following hypoxia, a common oxygen sensing and signaling pathway leads to increased Epo gene expression in both nervous and hepatoma cells; this pathway would be dependent on the redox-state of the brain. Furthermore, we show that the in vivo administration of CoCl(2) and DFX to mice induces an increased Epo mRNA level in the neocortex. As Epo protects the brain against ischemia, our in vivo experiments suggest that the use of molecules such as CoCl(2) or DFX, that provoke an increased Epo gene expression in the brain, could be useful in the development of potential therapeutic strategies for the treatment of hypoxic or ischemic brain injury. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10756076

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  62 in total

Review 1.  Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke.

Authors:  Zhongwu Liu; Michael Chopp
Journal:  Prog Neurobiol       Date:  2015-10-09       Impact factor: 11.685

Review 2.  Histological quantification of brain tissue inflammatory cell infiltration after focal cerebral infarction: a systematic review.

Authors:  Natanya S Russek; Matthew B Jensen
Journal:  Int J Neurosci       Date:  2013-09-18       Impact factor: 2.292

3.  Erythropoietin: still on the neuroprotection road.

Authors:  Nelvys Subirós; Diana García Del Barco; Rosa M Coro-Antich
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

Review 4.  How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson's disease?

Authors:  Jia Liu; Hong-Yun Huang
Journal:  Neurosci Bull       Date:  2007-11       Impact factor: 5.203

Review 5.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

6.  Effects of erythropoietin in murine-induced pluripotent cell-derived panneural progenitor cells.

Authors:  Nils Offen; Johannes Flemming; Hares Kamawal; Ruhel Ahmad; Wanja Wolber; Christian Geis; Holm Zaehres; Hans R Schöler; Hannelore Ehrenreich; Albrecht M Müller; Anna-Leena Sirén
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

7.  Erythropoietin negatively regulates pituitary ACTH secretion.

Authors:  Soumyadeep Dey; Tyler Scullen; Constance Tom Noguchi
Journal:  Brain Res       Date:  2015-03-09       Impact factor: 3.252

8.  A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.

Authors:  Béatrice Weber; Rémy Largillier; Isabelle Ray-Coquard; Gabriel Yazbek; Jérôme Meunier; Jérôme Alexandre; Jérôme Dauba; Dominique Spaeth; Rémy Delva; Florence Joly; Eric Pujade-Lauraine; Laure Copel
Journal:  Support Care Cancer       Date:  2013-02-19       Impact factor: 3.603

9.  Promotion of neurite outgrowth and protective effect of erythropoietin on the retinal neurons of rats.

Authors:  Yisheng Zhong; Huiping Yao; Lianfu Deng; Yu Cheng; Xiaoqing Zhou
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-09       Impact factor: 3.117

10.  Erythropoietin receptor (EpoR) agonism is used to treat a wide range of disease.

Authors:  Fabian Sanchis-Gomar; Carme Perez-Quilis; Giuseppe Lippi
Journal:  Mol Med       Date:  2013-04-30       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.